Literature DB >> 21159647

Loss of metallothionein predisposes mice to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-kappaB target genes.

Sarmila Majumder1, Satavisha Roy, Thomas Kaffenberger, Bo Wang, Stefan Costinean, Wendy Frankel, Anna Bratasz, Periannan Kuppusamy, Tsonwin Hai, Kalpana Ghoshal, Samson T Jacob.   

Abstract

Metallothioneins (MT) are potent scavengers of free radicals that are silenced in primary hepatocellular carcinomas (HCC) of human and rodent origin. To examine whether loss of MT promotes hepatocarcinogenesis, male Mt-1 and Mt-2 double knockout (MTKO) and wild-type (WT) mice were exposed to diethylnitrosamine (DEN) and induction of HCC was monitored at 23 and 33 weeks. The size and number of liver tumors, the ratio between liver and body weight, and liver damage were markedly elevated in the MTKO mice at both time points compared with the WT mice. At 23 weeks, MTKO mice developed HCC whereas WT mice developed only preneoplastic nodules suggesting that loss of MT accelerates hepatocarcinogenesis. MTKO tumors also exhibited higher superoxide anion levels. Although NF-κB activity increased in the liver nuclear extracts of both genotypes after DEN exposure, the complex formed in MTKO mice was predominantly p50/65 heterodimer (transcriptional activator) as opposed to p50 homodimer (transcriptional repressor) in WT mice. Phosphorylation of p65 at Ser276 causing its activation was also significantly augmented in DEN-exposed MTKO livers. NF-κB targets that include early growth response genes and proinflammatory cytokines were significantly upregulated in MTKO mice. Concurrently, there was a remarkable increase (∼100-fold) in Pai-1 expression; significant increase in c-Jun, c-Fos, c-Myc, Ets2, and ATF3 expressions; and growth factor signaling that probably contributed to the increased tumor growth in MTKO mice. Taken together, these results demonstrate that MTs protect mice from hepatocarcinogen-induced liver damage and carcinogenesis, underscoring their potential therapeutic application against hepatocellular cancer. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159647      PMCID: PMC3059562          DOI: 10.1158/0008-5472.CAN-10-2839

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Silencing of metallothionein-I gene in mouse lymphosarcoma cells by methylation.

Authors:  S Majumder; K Ghoshal; Z Li; Y Bo; S T Jacob
Journal:  Oncogene       Date:  1999-11-04       Impact factor: 9.867

2.  Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation.

Authors:  K Ghoshal; S Majumder; Z Li; X Dong; S T Jacob
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

3.  Transcriptional induction of metallothionein-I and -II genes in the livers of Cu,Zn-superoxide dismutase knockout mice.

Authors:  K Ghoshal; S Majumder; Z Li; T M Bray; S T Jacob
Journal:  Biochem Biophys Res Commun       Date:  1999-11-02       Impact factor: 3.575

Review 4.  Reactive oxygen species in cancer.

Authors:  Geou-Yarh Liou; Peter Storz
Journal:  Free Radic Res       Date:  2010-05

Review 5.  Regulation of metallothionein gene expression.

Authors:  K Ghoshal; S T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

6.  Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.

Authors:  C Isogai; W E Laug; H Shimada; P J Declerck; M F Stins; D L Durden; A Erdreich-Epstein; Y A DeClerck
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

7.  Regulation of metallothionein gene expression by oxidative stress and metal ions.

Authors:  G K Andrews
Journal:  Biochem Pharmacol       Date:  2000-01-01       Impact factor: 5.858

Review 8.  NF-kappaB as a critical link between inflammation and cancer.

Authors:  Michael Karin
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11       Impact factor: 10.005

9.  Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.

Authors:  Baidong Hou; Mesut Eren; Corrie A Painter; Joseph W Covington; John D Dixon; John A Schoenhard; Douglas E Vaughan
Journal:  J Biol Chem       Date:  2004-02-12       Impact factor: 5.157

10.  Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR.

Authors:  Vito R Cicinnati; Qingli Shen; Georgios C Sotiropoulos; Arnold Radtke; Guido Gerken; Susanne Beckebaum
Journal:  BMC Cancer       Date:  2008-11-27       Impact factor: 4.430

View more
  22 in total

1.  The tumor suppressor protein menin inhibits NF-κB-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma.

Authors:  Ding Gang; Hua Hongwei; Liu Hedai; Zhang Ming; Huang Qian; Liao Zhijun
Journal:  Mol Biol Rep       Date:  2012-12-06       Impact factor: 2.316

2.  Widespread Dysregulation of Long Noncoding Genes Associated With Fatty Acid Metabolism, Cell Division, and Immune Response Gene Networks in Xenobiotic-exposed Rat Liver.

Authors:  Kritika Karri; David J Waxman
Journal:  Toxicol Sci       Date:  2020-04-01       Impact factor: 4.849

3.  Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure.

Authors:  Shu-Hao Hsu; Bo Wang; Huban Kutay; Hemant Bid; Julia Shreve; Xiaoli Zhang; Stefan Costinean; Anna Bratasz; Peter Houghton; Kalpana Ghoshal
Journal:  Am J Pathol       Date:  2013-10-08       Impact factor: 4.307

4.  Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.

Authors:  Xiaofang Sun; Xiaohua Niu; Ruochan Chen; Wenyin He; De Chen; Rui Kang; Daolin Tang
Journal:  Hepatology       Date:  2016-05-24       Impact factor: 17.425

5.  Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.

Authors:  Kun-Yu Teng; Jianfeng Han; Xiaoli Zhang; Shu-Hao Hsu; Shun He; Nissar A Wani; Juan M Barajas; Linda A Snyder; Wendy L Frankel; Michael A Caligiuri; Samson T Jacob; Jianhua Yu; Kalpana Ghoshal
Journal:  Mol Cancer Ther       Date:  2016-12-15       Impact factor: 6.261

6.  ETS2 promotes epithelial-to-mesenchymal transition in renal fibrosis by targeting JUNB transcription.

Authors:  Fang Yao; Xiaojing Wang; Zhong-Kai Cui; Haibing Lan; Xiaolan Ai; Qiancheng Song; Zhenguo Chen; Jun Yang; Bingyi Wu; Xiaochun Bai
Journal:  Lab Invest       Date:  2019-10-22       Impact factor: 5.662

7.  Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor.

Authors:  Nahla E El-Ashmawy; Eman G Khedr; Hoda A El-Bahrawy; Eslam E Abd El-Fattah
Journal:  Clin Exp Med       Date:  2016-04-16       Impact factor: 3.984

8.  MicroRNA-140 acts as a liver tumor suppressor by controlling NF-κB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression.

Authors:  Akemi Takata; Motoyuki Otsuka; Takeshi Yoshikawa; Takahiro Kishikawa; Yohko Hikiba; Shuntaro Obi; Tadashi Goto; Young Jun Kang; Shin Maeda; Haruhiko Yoshida; Masao Omata; Hiroshi Asahara; Kazuhiko Koike
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

9.  Tanshinone IIA activates calcium-dependent apoptosis signaling pathway in human hepatoma cells.

Authors:  Zhi-Kai Dai; Jiang-Ke Qin; Jiao-E Huang; Yong Luo; Qing Xu; Hai-Lu Zhao
Journal:  J Nat Med       Date:  2011-08-19       Impact factor: 2.343

10.  IFN-γ and TNF-α synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFκB signaling.

Authors:  Lei Wang; Yinghua Zhao; Yi Liu; Kentaro Akiyama; Chider Chen; Cunye Qu; Yan Jin; Songtao Shi
Journal:  Stem Cells       Date:  2013-07       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.